Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5285 Target Snapshot

Mitogen-activated protein kinase kinase kinase 5 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,798Compounds
605Assays
0Approved Drugs
3,092.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Mitogen-activated protein kinase kinase kinase 5 shows late clinical disease relevance led by non-alcoholic fatty liver disease. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q99683. Start with non-alcoholic fatty liver disease, then reuse UniProt Q99683 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with non-alcoholic fatty liver disease, then reuse UniProt Q99683 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
non-alcoholic fatty liver disease

Mitogen-activated protein kinase kinase kinase 5 shows late clinical disease relevance led by non-alcoholic fatty liver disease. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with non-alcoholic fatty liver disease because it currently carries late clinical support. Linked drugs include SELONSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase kinase kinase 5 as ChEMBL target CHEMBL5285, mapped to UniProt Q99683. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase kinase kinase 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5285
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q99683
Mitogen-activated protein kinase kinase kinase 5
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitogen-activated protein kinase kinase kinase 5 is the right protein anchor across sources, using UniProt Q99683 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why non-alcoholic fatty liver disease is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMitogen-activated protein kinase kinase kinase 5
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ99683
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitogen-activated protein kinase kinase kinase 5
UniProt AccessionQ99683
Component TypeProtein
Sequence Length1374 aa

Mitogen-activated protein kinase kinase kinase 5

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Mitogen-activated protein kinase kinase kinase 5, mapped to UniProt Q99683. Sequence length is 1374 aa.

Mapped IDQ99683
Review nameMitogen-activated protein kinase kinase kinase 5
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Mitogen-activated protein kinase kinase kinase 5 shows late clinical disease relevance led by non-alcoholic fatty liver disease. 4 more disease programs remain visible in the same review block.

Late clinical Phase III
non-alcoholic fatty liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugSELONSERTIB
Late clinical Phase III
non-alcoholic steatohepatitis
1 linked drug · 1 direct · 1 efficacy
Linked drugSELONSERTIB
Clinical signal Phase II
diabetic nephropathy
1 linked drug · 1 direct · 1 efficacy
Linked drugSELONSERTIB
Clinical signal Phase II
Hepatitis, Alcoholic
1 linked drug · 1 direct · 1 efficacy
Linked drugSELONSERTIB
Clinical signal Phase II
pulmonary arterial hypertension
1 linked drug · 1 direct · 1 efficacy
Linked drugSELONSERTIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with non-alcoholic fatty liver disease because it currently carries late clinical support. Linked drugs include SELONSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasenon-alcoholic fatty liver disease
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Phase III
1
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC502,485.0
KI91.0
EC5027.0
KD489.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4283739 10.0 IC50 0.1 Preclinical
CHEMBL5787727 9.52 IC50 0.3 Preclinical
CHEMBL4290518 9.49 IC50 0.32 Preclinical
CHEMBL3969572 9.4 IC50 0.4 Preclinical
CHEMBL5746514 9.4 IC50 0.398 Preclinical
CHEMBL4294318 9.38 IC50 0.42 Preclinical
CHEMBL5559492 9.3 IC50 0.5 Preclinical
CHEMBL5559703 9.3 IC50 0.5 Preclinical
CHEMBL6039009 9.3 IC50 0.5 Preclinical
CHEMBL5760486 9.22 IC50 0.6 Preclinical
Distribution

pChEMBL Value Distribution

75
5.0
121
5.5
201
6.0
148
6.5
320
7.0
152
7.5
668
8.0
149
8.5
30
9.0
1
9.5
pChEMBL
Assay Landscape

Assay Landscape

605
Total Assays
1,383
Tested Compounds
2
Assay Types
Binding — 419 assays, 1,383 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 293 1,190 7.6
cell-based format 60 164 7.0
assay format 49 21 7.6
subcellular format 17 8 5.7
Functional — 186 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 186 1 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine